Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

DOPPS Lowers HCV Rates in Dialysis Patients

Key clinical point: HCV infection remains high in hemodialysis patients.

Major finding: HCV infection decreased from 2.9 to 1.2 per 100 patient-years in countries participating in the initial phase of DOPPS.

Study details: A database study of more than 82,000 dialysis patients.

Disclosures: A number of the authors reported being speakers or consultants for a variety of pharmaceutical companies; two of the authors are employees of Merck, which supported the work. Support for the ongoing DOPPS Program is provided without restriction on publications.

Citation:

Jadoul M et al. Kidney Int. 2019;95:939-47.